<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30611" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Trihexyphenidyl</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jilani</surname>
            <given-names>Talha N.</given-names>
          </name>
          <aff>HCA Healthcare Sunrise Health Graduate Medical Education Program</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sabir</surname>
            <given-names>Sarah</given-names>
          </name>
          <aff>Rawalpindi Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Talha Jilani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Sabir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30611.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Trihexyphenidyl is an anticholinergic agent primarily utilized for managing symptoms such as tremors, spasms, stiffness, and weak muscle control in patients with Parkinson disease. Approved by the FDA in June 2003 for idiopathic, postencephalitic, and arteriosclerotic Parkinsonism, this medication also addresses muscular conditions induced by specific central nervous system (CNS) drugs, including fluphenazine, haloperidol, and chlorpromazine. This activity&#x000a0;strengthens&#x000a0;healthcare professionals' understanding of trihexyphenidyl's indications, mechanism of action, administration methods, significant adverse effects, contraindications, toxicity, and monitoring protocols.</p>
        <p>By enhancing knowledge of trihexyphenidyl's pharmacology, healthcare professionals can better customize treatment plans to meet individual patient needs. This initiative stresses the role of interprofessional teams in optimizing trihexyphenidyl therapy, highlighting the need for clear role delineation and teamwork to enhance patient care. Such collaboration ensures effective communication and decision-making, which is vital for adjusting dosage regimens and reducing potential adverse reactions. Ultimately, this structured educational effort aims to equip healthcare professionals with the tools necessary for delivering targeted, safe, and personalized care to patients&#x000a0;with Parkinson disease and related disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of trihexyphenidyl.</p></list-item><list-item><p>Evaluate the adverse event profile of trihexyphenidyl.</p></list-item><list-item><p>Assess the toxicity profile and misuse potential for trihexyphenidyl.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from trihexyphenidyl treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30611&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30611">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30611.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Trihexyphenidyl/benzhexol is an anticholinergic medication used for the treatment of tremors, spasms, stiffness, and weak muscle control seen in patients with Parkinson disease.<xref ref-type="bibr" rid="article-30611.r1">[1]</xref><xref ref-type="bibr" rid="article-30611.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications&#x000a0;</bold>
</p>
        <p>Although it has been pertinent in clinical trials investigating the treatment of Parkinson disease since 1949,&#x000a0;trihexyphenidyl was approved for the management of all types of parkinsonism (idiopathic, postencephalitic, and arteriosclerotic) in June 2003 by the FDA.&#x000a0;Trihexyphenidyl is often used as an adjuvant therapy when treating these forms of parkinsonism with levodopa.<xref ref-type="bibr" rid="article-30611.r3">[3]</xref>&#x000a0;Trihexyphenidyl is also used to treat antipsychotic-induced parkinsonism&#x000a0;and extrapyramidal side effects (EPS), which are caused by first-generation antipsychotic drugs&#x000a0;such as fluphenazine, haloperidol, and chlorpromazine.<xref ref-type="bibr" rid="article-30611.r4">[4]</xref><xref ref-type="bibr" rid="article-30611.r5">[5]</xref><xref ref-type="bibr" rid="article-30611.r6">[6]</xref>&#x000a0;However, according to the prescribing information, the prophylactic use of trihexyphenidyl for preventing drug-induced parkinsonism during neuroleptic therapy is not recommended.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Trihexyphenidyl is used off-label to manage&#x000a0;dystonia in&#x000a0;patients with cerebral palsy.<xref ref-type="bibr" rid="article-30611.r7">[7]</xref><xref ref-type="bibr" rid="article-30611.r8">[8]</xref></p>
      </sec>
      <sec id="article-30611.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The precise mechanism of action of trihexyphenidyl is not completely understood; it appears to act on the parasympathetic nervous system by inhibiting efferent impulses directly. Structures innervated by the parasympathetic system, such as the salivary glands, eyes, and smooth muscles (directly and indirectly), are affected even at smaller doses. The direct central inhibition of cerebral motor centers may occur with higher doses. Research&#x000a0;suggests that the dopamine and M1 muscarinic receptors are affected.<xref ref-type="bibr" rid="article-30611.r9">[9]</xref><xref ref-type="bibr" rid="article-30611.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>The drug is well absorbed from the gastrointestinal tract. The onset of action occurs 60 minutes after an oral dose, with peak activity occurring after 2 hours.</p>
        <p><bold>Distribution:&#x000a0;</bold>Trihexyphenidyl achieves high concentration in the brain, facilitated by intralysosomal uptake.</p>
        <p><bold>Metabolism: </bold>Trihexyphenidyl is metabolized by hydroxylation of the alicyclic groups. Enterohepatic circulation is low.</p>
        <p><bold>Excretion: </bold>The estimated elimination half-life in adults is about 5 to 10 hours, but&#x000a0;some studies suggest an elimination half-life of up to&#x000a0;33 hours.<xref ref-type="bibr" rid="article-30611.r3">[3]</xref></p>
      </sec>
      <sec id="article-30611.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Trihexyphenidyl is available&#x000a0;as 2 mg and 5 mg oral tablets and as a&#x000a0;solution of 2 mg/5 mL.<xref ref-type="bibr" rid="article-30611.r11">[11]</xref><bold>&#x000a0;</bold>The dosage of&#x000a0;trihexyphenidyl HCl varies with the individual and is determined empirically. Clinicians should prescribe a low initial dose and increase the dose gradually, especially in adults older than 60. The patient can take the oral drug before or after meals; those with excessive xerostomia (due to trihexyphenidyl's anticholinergic effects)&#x000a0;can take the medication before meals, and those prone to nausea or excessive salivation&#x000a0;can take the drug after meals. Trihexyphenidyl is better tolerated with food in 3 separate doses daily. Higher doses, such as more than 10 mg/d, could be divided into&#x000a0;4 doses daily (1 taken with each meal and&#x000a0;1 at bedtime).</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold> Idiopathic Parkinsonism</bold>
</p>
        <p>As&#x000a0;initial therapy for idiopathic parkinsonism, 1 mg tablet of trihexyphenidyl is given on the first day. This dose could then increase by 2 mg accretions at intervals of around&#x000a0;4 days until a total dose of 6 to 10 mg is administered daily to the patient. The clinician determines the final daily optimal dosage for symptom control. Most patients show significant symptom improvement on 6 to 10 mg daily. Still, some postencephalitic&#x000a0;patients could require daily doses of around 12 to 15 mg for symptom management.<xref ref-type="bibr" rid="article-30611.r12">[12]</xref>&#x000a0;</p>
        <p>According to American Academy of Neurology guidelines, anticholinergics (including trihexyphenidyl) should be prescribed only&#x000a0;if the tremor is predominant.<xref ref-type="bibr" rid="article-30611.r13">[13]</xref>&#x000a0;According to NICE guidelines,&#x000a0;anticholinergics should not be used in patients with predominant dyskinesia or motor fluctuations.<xref ref-type="bibr" rid="article-30611.r14">[14]</xref>&#x000a0;According to the International Parkinson and Movement Disorder Society&#x000a0;guidelines, anticholinergics are clinically used for younger patients with no cognitive impairment.<xref ref-type="bibr" rid="article-30611.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold> Drug-Induced Parkinsonism</bold>
</p>
        <p>The optimal dose and dosing frequency of trihexyphenidyl required to control the extrapyramidal symptoms of commonly used CNS drugs, such as thioxanthenes and phenothiazines, is determined empirically by the clinician. The total daily dosage ranges from 5 to 15 mg for most patients, although there have been reported cases of symptoms being sufficiently controlled on as minimal as 1 mg daily. Therefore, the recommendation is to start treatment with a single dose of 1 mg. Failure of the extrapyramidal manifestations to resolve in a few hours could prompt an increase in dosage until achieving adequate control of symptoms. Adequate control of symptoms is sometimes possible in a shorter duration by briefly decreasing the CNS drug dosage when initiating trihexyphenidyl and gradually adjusting the dose of both drugs for the desired effects without the onset of extrapyramidal symptoms.<xref ref-type="bibr" rid="article-30611.r16">[16]</xref>&#x000a0;</p>
        <p>American Psychiatry Association guidelines (APA 2020)&#x000a0;suggest&#x000a0;that patients with acute dystonia&#x000a0;due to antipsychotic therapy be treated with anticholinergic medication like trihexyphenidyl. In addition,&#x000a0;APA suggests that for&#x000a0;drug-induced parkinsonism due to&#x000a0;antipsychotic treatment,&#x000a0;reduce the&#x000a0;dose of the antipsychotic drug,&#x000a0;change to another antipsychotic drug, or treat with anticholinergic medications.<xref ref-type="bibr" rid="article-30611.r17">[17]</xref></p>
        <p>
<bold> Concomitant Use with Levodopa</bold>
</p>
        <p>The usual dose of levodopa and trihexyphenidyl may require reduction when administering both of these&#x000a0;drugs concomitantly. Any adjustment in dosage needs to be made carefully, depending on the level of symptom control and subsequent adverse effects. An adequate dosage for symptom control with minimal adverse effects is generally around 3 to 6 mg daily, given in divided doses.<xref ref-type="bibr" rid="article-30611.r7">[7]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The manufacturer's labeling does not provide information regarding dose adjustment for hepatic impairment. Use with caution.</p>
        <p><bold>Renal impairment: </bold>The manufacturer's labeling does not provide information regarding dose adjustment for renal impairment. Use with caution.</p>
        <p><bold>Pregnancy considerations: </bold>Trihexyphenidyl crosses the placenta&#x000a0;and is classified as a former FDA pregnancy risk factor class C medication. Miscarriage and molar pregnancy have been reported. In a cohort of 2323 patients exposed to anticholinergics drugs, significant congenital disabilities were not increased. However, miscarriage and molar pregnancy have been reported in a few cases. Use with caution.<xref ref-type="bibr" rid="article-30611.r11">[11]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Prolonged trihexyphenidyl use may suppress lactation, but a single dose is not likely to interrupt breastfeeding. During long-term use, clinicians should monitor for signs of decreased lactation.<xref ref-type="bibr" rid="article-30611.r12">[12]</xref></p>
        <p><bold>Older patients (potentially inappropriate medicine):</bold> According to the American Geriatric Society (Beers criteria), trihexyphenidyl is a PIM for use in older adults. Older adults have an increased risk of anticholinergic adverse effects like cognitive impairment, confusion, delirium, constipation, and urinary retention.&#x000a0;Trihexyphenidyl is also not recommended to manage antipsychotic drug-associated extrapyramidal effects in older adults. Consequently, older patients should be prescribed&#x000a0;lower doses of trihexyphenidyl and monitored closely.<xref ref-type="bibr" rid="article-30611.r18">[18]</xref>&#x000a0;One case report indicated that trihexyphenidyl improves apraxia of eyelid opening seen in Parkinson disease; further research is required.<xref ref-type="bibr" rid="article-30611.r19">[19]</xref></p>
        <p><bold>Pediatric patients:</bold> Trihexyphenidyl is used off-label to treat dystonia and can also reduce drooling/sialorrhea in children with developmental disabilities.<xref ref-type="bibr" rid="article-30611.r8">[8]</xref><xref ref-type="bibr" rid="article-30611.r20">[20]</xref><xref ref-type="bibr" rid="article-30611.r21">[21]</xref></p>
      </sec>
      <sec id="article-30611.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of trihexyphenidyl are frequently dose-dependent but usually decrease over time as tolerance develops and the body adapts to the drug. Even with all of the adverse effects considered, trihexyphenidyl demonstrated dramatic and consistent improvement of neurologic defects in people between the ages of 16 and 86 over a 5-year course. Confusion and delirium frequently occur in older patients or&#x000a0;patients with&#x000a0;psychiatric disorders.&#x000a0;</p>
        <p>Adverse effects of trihexyphenidyl according to system organ classification (SOC) include but are not limited to:</p>
        <p><bold>Ocular effects:</bold> Mydriasis may present in patients with and without photophobia. This condition can lead to blurred vision or precipitate narrow-angle glaucoma by angle closure, which increases intraocular pressure.<xref ref-type="bibr" rid="article-30611.r22">[22]</xref></p>
        <p><bold>CNS effects:</bold> Frequently reported&#x000a0;adverse effects&#x000a0;include headache, dizziness, drowsiness, and vertigo. Anxiety, nervousness, confusion, and agitation occurred in patients on higher doses. Trihexyphenidyl also&#x000a0;causes a short-acting euphoric and mood-elevating effect, which is why it is&#x000a0;a drug of potential misuse.<xref ref-type="bibr" rid="article-30611.r23">[23]</xref>&#x000a0;Additionally, there have been cases involving disruption of normal sleep architecture (REM sleep depression).&#x000a0;Trihexyphenidyl&#x000a0;may also lower the seizure threshold, requiring caution in people with epilepsy or other seizure disorders.<xref ref-type="bibr" rid="article-30611.r24">[24]</xref><bold>&#x000a0;</bold>Long-term use&#x000a0;has the potential to develop&#x000a0;Alzheimer's disease in&#x000a0;preclinical studies.<xref ref-type="bibr" rid="article-30611.r25">[25]</xref></p>
        <p><bold>Peripheral adverse effects:</bold>&#x000a0;As with other anticholinergics, impaired sweating, dry mouth, abdominal discomfort, nausea, urinary retention, and constipation are frequently seen (patients require monitoring for long-term use).<xref ref-type="bibr" rid="article-30611.r26">[26]</xref>&#x000a0;Some patients also develop tachycardia. Although allergic reactions are infrequent, they&#x000a0;can occur with trihexyphenidyl use. Fatal hyperthermia and severe anhidrosis are also possible,&#x000a0;so caution is advised when using the drug during exercise or in hot weather.<xref ref-type="bibr" rid="article-30611.r27">[27]</xref></p>
        <p><bold>Tolerance:</bold>&#x000a0;Tolerance could develop with prolonged drug use, and dosing adjustments may be necessary.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Potassium chloride is contraindicated in patients with inadequate gastric emptying. Anticholinergic agents impair&#x000a0;motility and increase the contact time of potassium chloride with gastric mucosa, leading to gastritis, peptic ulcer, and increased risk of upper GI bleeding.<xref ref-type="bibr" rid="article-30611.r28">[28]</xref>&#x000a0;Severe dizziness has been reported in patients treated with rivaroxaban and trihexyphenidyl. The mechanism of this interaction is unknown.<xref ref-type="bibr" rid="article-30611.r29">[29]</xref>&#x000a0;Alcohol, barbiturates, cannabinoids, and opiates may have additive effects with trihexyphenidyl; concurrent use should be avoided.<xref ref-type="bibr" rid="article-30611.r30">[30]</xref></p>
      </sec>
      <sec id="article-30611.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Per the manufacturer's labeling, trihexyphenidyl is contraindicated in those with hypersensitivity to the drug (trihexyphenidyl HCl) or excipients.&#x000a0;Trihexyphenidyl is also contraindicated in patients with narrow-angle glaucoma because it possesses anticholinergic activity that could cause mydriasis, further narrowing the lens angle, increasing the IOP, and worsening the condition.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Clinicians should avoid abrupt withdrawal of trihexyphenidyl in patients undergoing treatment for Parkinsonism symptoms, as this could cause an acute exacerbation of existing symptoms. In addition, there are reports of neuroleptic malignant syndrome in patients who had an abrupt withdrawal from treatment.<xref ref-type="bibr" rid="article-30611.r31">[31]</xref><xref ref-type="bibr" rid="article-30611.r32">[32]</xref></p>
      </sec>
      <sec id="article-30611.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Trihexyphenidyl is not strictly contraindicated for patients with liver, kidney, or cardiac disorders, but recommendations are to monitor these patients closely when using the drug. Additionally, patients with hypertension should also have their blood pressure monitored&#x000a0;regularly during&#x000a0;therapy.</p>
        <p>Some patients may require the indefinite use of trihexyphenidyl, and since it has properties similar to atropine, constant and long-term supervision should be implemented to prevent allergic and other unwanted reactions. Because of its parasympathetic activity, trihexyphenidyl should be used precautiously and monitored closely in patients with obstructive genitourinary or gastrointestinal diseases, glaucoma, and older males with prostatic hypertrophy.<xref ref-type="bibr" rid="article-30611.r22">[22]</xref>&#x000a0;Older patients commonly develop an increased sensitivity to these types of drugs and require strict regulation of their dosage.</p>
        <p>In 2008, there were reports that Iraqi police and soldiers were using trihexyphenidyl for recreational purposes and other prescription drugs. Reportedly, the drugs were taken as they seemed to relieve combat stress. Reports indicate that trihexyphenidyl misuse can be seen in delusional disorders. Monitor for signs of misuse using prescription drug monitoring programs.<xref ref-type="bibr" rid="article-30611.r33">[33]</xref><xref ref-type="bibr" rid="article-30611.r34">[34]</xref><xref ref-type="bibr" rid="article-30611.r35">[35]</xref></p>
      </sec>
      <sec id="article-30611.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>As with some other antiparkinsonian medications, trihexyphenidyl is known to be&#x000a0;a drug of misuse. Misuse has been reported primarily in patients with chronic schizophrenia and those with other substance use disorders.&#x000a0;A recent systematic review published in 2022&#x000a0;reveals an alarming trend of&#x000a0;misuse&#x000a0;of trihexyphenidyl.&#x000a0;Benzhexol/Trihexyphenidyl (THP)&#x000a0;is one of the most misused anticholinergic drugs.&#x000a0;Trihexyphenidyl is frequently combined with&#x000a0;benzodiazepines,&#x000a0;alcohol, cannabis,&#x000a0;amphetamines, opioids, LSD, PCP,&#x000a0;nicotine, and cocaine.<xref ref-type="bibr" rid="article-30611.r23">[23]</xref></p>
        <p>Trihexyphenidyl toxicity resembles atropine intoxication (antimuscarinic effects) with xerostomia, anhidrosis, mydriasis, nausea/vomiting, tachycardia, hyperpyrexia, decreased bowel and bladder movements, rash, and hyperthermia, which usually accompany excessive doses. CNS symptoms observed with overdose include confusion, restlessness, agitation, incoordination, paranoid and psychotic reactions, delirium, and hallucinations. Reports exist of CNS depression leading to coma, respiratory and circulatory failure, and death in cases of severe overdose.<xref ref-type="bibr" rid="article-30611.r36">[36]</xref> If the overdose does not receive prompt treatment, it could be fatal, especially in&#x000a0;younger children.<xref ref-type="bibr" rid="article-30611.r10">[10]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The management of overdoses is always supportive; establish adequate airway patency immediately. Physostigmine is a specific antagonist that acts centrally and peripherally to counter the antimuscarinic effects. Convulsions and hyperactivity require management with diazepam, but with caution, as the risk of CNS depression could be exacerbated. Acidosis and hypoxia should have appropriate therapy. Dysrhythmias should not be treated with antiarrhythmic drugs. Atonic bladder and bowel are treatable with carbachol.</p>
      </sec>
      <sec id="article-30611.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians usually prescribe trihexyphenidyl for specific indications such as drug-induced parkinsonism. As discussed above, neurologists, psychiatrists, and movement disorder specialists play an essential role in managing patients who require trihexyphenidyl therapy. Pharmacists should perform medication reconciliation and inform the clinicians of interactions. Nursing should monitor for compliance, signs of misuse, and clinical improvement. Clinicians (MDs, DOs, PAs, and NPs) play an important role in prescribing trihexyphenidyl and restrict its usage for only essential conditions. The utilization of prescription drug monitoring programs (PDMP) is&#x000a0;recommended&#x000a0;due to&#x000a0;reported misuse of trihexyphenidyl.<xref ref-type="bibr" rid="article-30611.r37">[37]</xref>&#x000a0;</p>
        <p>In light of the recent systematic review, concomitant drug&#x000a0;misuse is common with trihexyphenidyl; medical toxicologists should be consulted.&#x000a0;Due to the potential toxicity of&#x000a0;trihexyphenidyl, its dosing and management require an interprofessional healthcare team consisting of the clinician, nurse, and pharmacist monitoring the patient for complications and communicating any concerns to the healthcare team. This interprofessional approach drives better outcomes while limiting the potential for drug misuse or adverse events. A respective study suggests that&#x000a0;direct care&#x000a0;of patients under&#x000a0;medical toxicologist&#x000a0;supervision&#x000a0;is associated with significant reductions&#x000a0;in length of hospital stay, costs, and mortality in patients hospitalized with a drug overdose.<xref ref-type="bibr" rid="article-30611.r38">[38]</xref></p>
      </sec>
      <sec id="article-30611.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30611&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30611">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30611/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30611">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30611.s11">
        <title>References</title>
        <ref id="article-30611.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McInnis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petursson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal of trihexyphenidyl.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-303</page-range>
            <pub-id pub-id-type="pmid">3984771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>JST</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Piao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dopaminergic versus anticholinergic treatment effects on physiologic complexity of hand tremor in Parkinson's disease: A&#x000a0;randomized crossover study.</article-title>
            <source>CNS Neurosci Ther</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>e14516</fpage>
            <pub-id pub-id-type="pmid">37905677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brocks</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective.</article-title>
            <source>J Pharm Pharm Sci</source>
            <year>1999</year>
            <season>May-Aug</season>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">10952768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisidagama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Selladurai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Isetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serra-Mestres</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.</article-title>
            <source>Medicines (Basel)</source>
            <year>2021</year>
            <month>May</month>
            <day>26</day>
            <volume>8</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">34073269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marmol</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Margolesky</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2022</year>
            <volume>18</volume>
            <fpage>1129</fpage>
            <page-range>1129-1142</page-range>
            <pub-id pub-id-type="pmid">36573102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wubeshet</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Desse</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study.</article-title>
            <source>BMC Psychiatry</source>
            <year>2019</year>
            <month>Jan</month>
            <day>18</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">30658604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harvey</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Reddihough</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Trihexyphenidyl for dystonia in cerebral palsy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD012430</fpage>
            <pub-id pub-id-type="pmid">29763510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maharjan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dahal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khati</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Status Dystonicus with Atypical Presentation in Developmentally Delay Child: A Case Report.</article-title>
            <source>JNMA J Nepal Med Assoc</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>60</volume>
            <issue>252</issue>
            <fpage>739</fpage>
            <page-range>739-742</page-range>
            <pub-id pub-id-type="pmid">36705216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giachetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giraldo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ladinsky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine.</article-title>
            <source>Br J Pharmacol</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">2432979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berke</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Addiction, dopamine, and the molecular mechanisms of memory.</article-title>
            <source>Neuron</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-32</page-range>
            <pub-id pub-id-type="pmid">10774721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robottom</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review.</article-title>
            <source>Neurologist</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>340</fpage>
            <page-range>340-1</page-range>
            <pub-id pub-id-type="pmid">22045287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Trihexyphenidyl</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyasaki</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Suchowersky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2002</year>
            <month>Jan</month>
            <day>08</day>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">11781398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <article-title>Parkinson's disease: summary of updated NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Feb</month>
            <day>28</day>
            <volume>364</volume>
            <fpage>l961</fpage>
            <pub-id pub-id-type="pmid">30819680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Katzenschlager</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Bie</surname>
                <given-names>RMA</given-names>
              </name>
              <name>
                <surname>Seppi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>C</given-names>
              </name>
              <collab>Movement Disorder Society Evidence-Based Medicine Committee</collab>
            </person-group>
            <article-title>International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.</article-title>
            <source>Mov Disord</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1248</fpage>
            <page-range>1248-1266</page-range>
            <pub-id pub-id-type="pmid">29570866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Meijer</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <chapter-title><italic>VPS13D</italic> Movement Disorder</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>LJH</given-names>
              </name>
              <name>
                <surname>Gripp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2019</year>
            <month>2</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30789691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takaku</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Trihexyphenidyl on Apraxia of Eyelid Opening in Parkinsonism: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>e56232</fpage>
            <pub-id pub-id-type="pmid">38618350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Westbury</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guzys</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Reddihough</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic medications for reducing drooling in children with developmental disability.</article-title>
            <source>Dev Med Child Neurol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-353</page-range>
            <pub-id pub-id-type="pmid">31495925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradford</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Parman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Management of Sialorrhea in Neonatal and Pediatric Patients.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2024</year>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-21</page-range>
            <pub-id pub-id-type="pmid">38332959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lachkar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bouassida</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced acute angle closure glaucoma.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">17301614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiappini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miuli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Semeraro</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Mancusi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santovito</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Di Carlo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pettorruso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corkery</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schifano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Giannantonio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Misuse of Anticholinergic Medications: A Systematic Review.</article-title>
            <source>Biomedicines</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35203563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-&#x000c1;lvarez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sevilla-Llewellyn-Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ag&#x000fc;era-Ortiz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic Drugs in Geriatric Psychopharmacology.</article-title>
            <source>Front Neurosci</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>1309</fpage>
            <pub-id pub-id-type="pmid">31866817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Long-term trihexyphenidyl exposure alters neuroimmune response and inflammation in aging rat: relevance to age and Alzheimer's disease.</article-title>
            <source>J Neuroinflammation</source>
            <year>2016</year>
            <month>Jul</month>
            <day>01</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>175</fpage>
            <pub-id pub-id-type="pmid">27411393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Begbie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kubba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sabharwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute colonic pseudo-obstruction in a child taking trihexyphenidyl for drooling: Prescribers beware.</article-title>
            <source>Int J Pediatr Otorhinolaryngol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>932</fpage>
            <page-range>932-934</page-range>
            <pub-id pub-id-type="pmid">25912627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamshidi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The hot patient: acute drug-induced hyperthermia.</article-title>
            <source>Aust Prescr</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">30765906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gueta</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Markovits</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Halkin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loebstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Concomitant oral potassium chloride and anticholinergic therapy is associated with upper gastrointestinal bleeding: A cohort study.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>2064</fpage>
            <page-range>2064-2069</page-range>
            <pub-id pub-id-type="pmid">33068044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Le Goff</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaillon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Triquenot-Bagan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malt&#x000ea;te</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?</article-title>
            <source>Presse Med</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1203</fpage>
            <page-range>1203-4</page-range>
            <pub-id pub-id-type="pmid">26433836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torrents</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferr&#x000e9;</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Konareff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hemery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sherwin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lassalle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scerra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Misuse of Trihexyphenidyl (Artane) on R&#x000e9;union Island.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-253</page-range>
            <pub-id pub-id-type="pmid">29620695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanamoorthy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Loganathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.</article-title>
            <source>Asian J Psychiatr</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>12</volume>
            <fpage>158</fpage>
            <page-range>158-9</page-range>
            <pub-id pub-id-type="pmid">25440569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2020</year>
            <month>May</month>
            <volume>99</volume>
            <issue>20</issue>
            <fpage>e20129</fpage>
            <pub-id pub-id-type="pmid">32443324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nishanth</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Mahapatra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balhara</surname>
                <given-names>YPS</given-names>
              </name>
            </person-group>
            <article-title>Trihexyphenidyl Misuse in Delusional Disorder.</article-title>
            <source>J Neurosci Rural Pract</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-430</page-range>
            <pub-id pub-id-type="pmid">30069107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frauger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thirion</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chanut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Natali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Debruyne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saillard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pradel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reggio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Micallef</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Misuse of trihexyphenidyl (Artane, Parkinane): recent trends].</article-title>
            <source>Therapie</source>
            <year>2003</year>
            <season>Nov-Dec</season>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>541</fpage>
            <page-range>541-7</page-range>
            <pub-id pub-id-type="pmid">15058500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponnapalli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murcko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wertheim</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Systematic Literature Review of Prescription Drug Monitoring Programs.</article-title>
            <source>AMIA Annu Symp Proc</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>1478</fpage>
            <page-range>1478-1487</page-range>
            <pub-id pub-id-type="pmid">30815193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petkovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Durendi&#x00107;-Brenesel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dolai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samojlik</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fatal intoxication because of trihexyphenidyl.</article-title>
            <source>J Forensic Sci</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1383</fpage>
            <page-range>1383-6</page-range>
            <pub-id pub-id-type="pmid">21644988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Teeter</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Edlund</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.</article-title>
            <source>Res Social Adm Pharm</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>754</fpage>
            <page-range>754-760</page-range>
            <pub-id pub-id-type="pmid">30243575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30611.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curry</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gerkin</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of a medical toxicology admitting service on length of stay, cost, and mortality among inpatients discharged with poisoning-related diagnoses.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">25127915</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
